Indiziert in
  • Öffnen Sie das J-Tor
  • Genamics JournalSeek
  • CiteFactor
  • Kosmos IF
  • Scimago
  • Ulrichs Zeitschriftenverzeichnis
  • Elektronische Zeitschriftenbibliothek
  • RefSeek
  • Hamdard-Universität
  • EBSCO AZ
  • Verzeichnis der Abstract-Indexierung für Zeitschriften
  • OCLC – WorldCat
  • Proquest-Vorladungen
  • Gelehrtersteer
  • STRASSE
  • Virtuelle Bibliothek für Biologie (vifabio)
  • Publons
  • Genfer Stiftung für medizinische Ausbildung und Forschung
  • Google Scholar
Teile diese Seite
Zeitschriftenflyer
Flyer image

Abstrakt

Clinical Significance of Circulating Tumor Cells in Pancreatic Cancer

Guangfu Li, Yue Huang, Yariswamy Manjunath, Eric T Kimchi, Jussuf T Kaifi and Kevin F Staveley-O’Carroll

Pancreatic cancer (PC) is a highly aggressive malignancy with limited therapeutic options. Early and accurate detection is critically important for successful cancer treatment. Currently, the most widely used and best validated marker for pancreatic cancer is carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA). However, inadequate sensitivity and specificity limit the use of CA 19-9 and CEA in the early screening and diagnosis of pancreatic cancer. During past ten years, circulating tumor cells (CTCs) as a new liquid biomarker have received enormous attention in cancer diagnosis and management. Although CTCs are extremely rare and challenging to be isolated, their clinical significance has extensively been investigated in numerous clinical trials. In this review, we summarize the CTC application in translational pancreatic cancer research and its outlook in the future, specifically evaluating its clinical potential in pancreatic cancer diagnosis, prognosis, and treatments. Development of sensitive, specific, and reliable methods is expected towards a major impact on our ability in cancer management.

Haftungsausschluss: Dieser Abstract wurde mit Hilfe von Künstlicher Intelligenz übersetzt und wurde noch nicht überprüft oder verifiziert.